Tarsons Products Limited

Downstream

Downstream, buyers that run on refined fuel, such as IndiGo, the airline that buys fuel from Indian Oil, and Maruti Suzuki, the car maker supplied by Indian Oil, face higher running and freight costs that feed into tickets and vehicle costs with a lag.

Upstream

Upstream, firms that feed and support refineries, such as Deep Industries, which provides oilfield services to Reliance Industries, and GAIL India, which supplies gas to Indian Oil, see mixed effects as costlier crude squeezes refiner budgets but diversified sourcing can lift service and logistics work.

Business

Refiners buy fewer discounted Russian barrels and more from other sources, pushing up their fuel-making costs; terminal operators store and move extra volumes, while makers of adhesives, explosives and lab plastics pay more for resins and pass part on slowly.

Capital

Investors turn cautious on refiners and crude-heavy chemical makers and lean a little toward storage terminals and oilfield service firms, with Brent near 100.5 dollars keeping sentiment nervous.

Automobile and Auto Components

Higher fuel and freight costs weigh on vehicle makers and parts sellers.

Chemicals

Makers of adhesives, fragrances and speciality inputs face higher oil-linked costs.

Fast Moving Consumer Goods

Daily-goods makers absorb higher packaging and freight bills with a delay.

Oil, Gas & Consumable Fuels

Refiners pay more for replacement crude, trimming near-term margins.

Power

Costlier fuel oil and freight add mild pressure to power generators using oil-linked inputs.

Commodity

Crude Oil Brent

Move series

Crude Oil Brent

Note

Brent crude at 100.5 dollars a barrel, up 13.97% in a month, with a 3.694% move used for margins; the hit was copied into signals for Indian Oil (176.6 bps on 47.8% cost weight), Tarsons Products (103.4 bps) and S H Kelkar (88.65 bps).

Shock

price

Unit

USD/barrel

Cascade chain

• Russian crude share falls → refiners buy costlier replacement barrels
• Brent +3.694% → resin and chemical inputs dearer → margins -88.65 to -176.6 bps
• Higher fuel and freight → transport, paints, tyres and daily goods pass costs with a lag

Pattern name

Crude Oil Cascade

Patterns

• Crude Oil Cascade

Sectors queried

• Cement
• Chemicals
• FMCG
• Power

Immediate

In the next 1-7 days refiners flag costlier crude mix and traders mark down refiner and plastics shares slightly.

Medium term

Over 1-6 months margins recover if Russian discounts return or Brent cools, else price hikes spread to daily goods and freight.

Short term

Over 1-4 weeks chemical, paint and packaging makers guide to softer margins while terminals report busier handling.

Downstream

Downstream, fuel sellers such as Indian Oil and Bharat Petroleum pass crude on to drivers and airlines (Indian Oil even supplies Maruti, Tata Motors and IndiGo), so dearer crude raises costs for transport and vehicle demand.

Upstream

Upstream, crude producers and oilfield service firms (explorers, drillers, offshore support) gain pricing power as supply fears lift crude — the pack flags explorers with a positive crude link.

Business

Business demand shifts rather than grows: refiners and fuel sellers (Indian Oil, Bharat Petroleum, Reliance's fuel arm) pay more for crude without matching pump-price room, squeezing margins, while upstream producers see stronger takings on each barrel sold.

Capital

Investor money tends to hide from margin-squeezed refiners and crude-linked chemical buyers toward upstream producers, though a single strike headline usually moves prices only modestly.

Chemicals

Cost push: makers using crude-linked inputs (aromatics, polymers, fragrances) see margins narrow while oil stays high.

Fast Moving Consumer Goods

Mild drag: packaging and freight costs edge up with crude, trimming consumer-goods margins slightly.

Oil, Gas & Consumable Fuels

Split: refiners and fuel sellers face a margin squeeze from dearer crude while explorers gain on richer selling prices.

Commodity

Crude Oil Brent

Move series

Crude Oil Brent

Note

Brent crude spiked on the refinery-strike supply scare (USD 98.4 a barrel, up 15.37% in a month). The pack's resolved-move margin bps were copied exactly onto Indian Oil (-15.49), Tarsons (-9.076) and S H Kelkar (-7.78); null kept where the pack carried none.

Shock

price

Unit

USD/barrel

Cascade chain

• Russian refinery hit by drones → crude supply fears
• Brent near USD 98.4 (+15.37% in a month) → refiner crude costs up
• Refiner margins squeezed (Indian Oil margin bps -15.49 on resolved move)
• Crude-linked chemical and polymer input costs up (Tarsons -9.076, S H Kelkar -7.78 bps)
• Fuel and freight costs push FMCG, airline and auto costs up

Pattern name

Crude Oil Cascade

Patterns

• Crude Oil Cascade

Sectors queried

• Cement
• Chemicals
• FMCG
• Power

Immediate

Crude stays jumpy and refiner shares wobble as traders price the refinery outage and the next drone headline.

Medium term

A longer outage would force fuel-price or margin decisions and lasting chemical cost pass-through; otherwise this fades as one headline.

Short term

If strikes continue, refining margins and chemical input costs stay squeezed; a lull in attacks lets crude and margins settle.

Downstream

Hospitals, distributors and pharmacies pay the same device prices as before, so nothing changes in their costs or stocking; the cap would only have mattered if it had been imposed.

Upstream

Almost no upstream effect: plastic, resin and component suppliers to device makers see steady order volumes because no price or quantity changes — only a proposed margin rule that never took effect.

Business

No demand is created or destroyed — hospitals order the same quantities at the same prices. This is purely about who keeps the margin on each device sold, and for now the answer stays unchanged.

Capital

At most a small relief bid in Poly Medicure shares; far too narrow an event to pull money into or out of Healthcare as a whole, so no rotation.

Healthcare

Ripple stays inside Healthcare's small device corner: mild sentiment relief for device makers, neutral for hospitals, diagnostics and every drug maker — no second-order effects anywhere else.

Immediate

1-7 days: mild relief sentiment in POLYMED shares, perhaps +1-2%, while the rest of Healthcare ignores the story.

Medium term

1-6 months: either a new legal route resets device trade margins (mild negative for makers) or the proposal fades and today's margins stand.

Short term

1-4 weeks: watch for a government response — an amended price-control order, an expanded drug schedule or a fresh bill would revive the margin-cap threat and erase the relief.

Downstream

Distributors and pharmacies stock more new products; hospitals mostly unaffected.

Upstream

API and intermediate makers gain volumes as more launches need ingredients.

Business

Approval queues shorten; API/CDMO order books lengthen; patients access drugs sooner.

Capital

Money rotates into launch-heavy pharma and quality API names; avoids weak-balance-sheet theme traps.

Healthcare

Pharma and CDMO positive with a lag; hospitals neutral; weak names are value traps.

Immediate

Pharma stocks firm 1-3% on sentiment; weak names jump most (sell the jump).

Medium term

Actual approval acceleration over 1-3 years compounds launch-heavy winners.

Short term

Draft details and implementation dates decide how much is real vs hope.

Downstream

US clients of Morpeth qualify backup suppliers slowly; no drug shortages indicated.

Upstream

No direct supply-chain link — this is a plant-quality event, not a supply disruption; API suppliers to Morpeth see minor order delays.

Business

CDMO clients slow new Piramal orders and audit harder; no demand transfers at scale to peers.

Capital

Money trims small-pharma exposure on regulatory headlines; rotates to large quality pharma and hospitals-on-facts.

Healthcare

CDMO/API sentiment hit; hospitals untouched operationally; large pharma flat per precedent.

Immediate

Piramal stock down 2-5% on the headline; small peers dip 1-3% on sentiment.

Medium term

Clean re-inspection closes the episode; warning letter or import alert would extend damage to quarters.

Short term

Company corrective-action response and FDA classification (VAI vs OAI) decide whether this fades or escalates.